Latest Articles

Publication Date
All News Scientific
Pembrolizumab Plus Chemotherapy Shows Long-Term OS Benefit in Advanced/Recurrent Endometrial Cancer - OncLive

Pembrolizumab Plus Chemotherapy Shows Long-Term OS Benefit in Advanced/Recurrent Endometrial Cancer OncLive

Published: May 29, 2026, 11:57 p.m.
Read Full Article
Dostarlimab Plus Chemotherapy Yields Curative Potential in dMMR/MSI-H Endometrial Cancer - CancerNetwork

Dostarlimab Plus Chemotherapy Yields Curative Potential in dMMR/MSI-H Endometrial Cancer CancerNetwork

Published: May 29, 2026, 10:40 p.m.
Read Full Article
Dostarlimab Plus Chemotherapy Demonstrates Sustained Disease Control in dMMR/MSI-H Advanced Endometrial Cancer - HMP Global Learning Network

Dostarlimab Plus Chemotherapy Demonstrates Sustained Disease Control in dMMR/MSI-H Advanced Endometrial Cancer HMP Global Learning Network

Published: May 26, 2026, 4:46 p.m.
Read Full Article
Cadonilimab Plus Chemotherapy Shows Strong Efficacy and Safety in Advanced or Recurrent Endometrial Cancer - OncLive

Cadonilimab Plus Chemotherapy Shows Strong Efficacy and Safety in Advanced or Recurrent Endometrial Cancer OncLive

Published: April 12, 2026, 2:35 p.m.
Read Full Article
Neoadjuvant Chemotherapy Followed by Radical Cytoreductive Surgery in Serous Endometrial Carcinoma With Inguinal Lymph Node Metastasis: A Case Report - Cureus

Neoadjuvant Chemotherapy Followed by Radical Cytoreductive Surgery in Serous Endometrial Carcinoma With Inguinal Lymph Node Metastasis: A Case Report Cureus

Published: April 9, 2026, 9:38 a.m.
Read Full Article
Real-World Use of Dostarlimab Plus Chemotherapy in Advanced or Recurrent dMMR Endometrial Cancer - epi-phare

Real-World Use of Dostarlimab Plus Chemotherapy in Advanced or Recurrent dMMR Endometrial Cancer epi-phare

Published: March 9, 2026, 10:32 a.m.
Read Full Article
Endometrial cancer: AIFA approves immunotherapy with chemotherapy for all patients. - lamilano.it

Endometrial cancer: AIFA approves immunotherapy with chemotherapy for all patients. lamilano.it

Published: Feb. 23, 2026, 1:30 p.m.
Read Full Article
Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer - BioSpace

Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer BioSpace

Published: Feb. 4, 2026, 4:47 a.m.
Read Full Article
Gsk - Quebec To Reimburse Jemperli Plus Chemotherapy Via Ramq For Primary Advanced/First Recurrent Endometrial Cancer - TradingView

Gsk - Quebec To Reimburse Jemperli Plus Chemotherapy Via Ramq For Primary Advanced/First Recurrent Endometrial Cancer TradingView

Published: Feb. 3, 2026, 1:11 p.m.
Read Full Article
Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer - Newswire Canada

Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer Newswire …

Published: Feb. 3, 2026, 1 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!